Company Overview

Scholar Rock Holding Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel medicines that selectively target the activation of growth factors involved in serious diseases. The company operates within the biopharmaceutical and biotechnology industries, with a core emphasis on neuromuscular disorders, cardiometabolic diseases, and oncology. Its scientific approach centers on developing monoclonal antibodies that inhibit the activation of latent growth factors, rather than blocking signaling after activation, which the company positions as a differentiated therapeutic strategy.

The company’s primary value driver is its proprietary antibody platform targeting the transforming growth factor beta (TGF‑β) superfamily, with lead programs addressing conditions with high unmet medical need. Scholar Rock was founded in 2012 as a spin-out from academic research conducted at Harvard University and Dana‑Farber Cancer Institute. It became a publicly traded company in 2018 following its initial public offering and is listed on the Nasdaq under the ticker SRRK.

Business Operations

Scholar Rock’s operations are organized around research, clinical development, and eventual commercialization of biologic therapies. The company does not currently generate product revenue and instead relies on capital from equity offerings, collaborations, and upfront payments to fund operations. Its most advanced clinical program is apitegromab, an antibody designed to inhibit myostatin activation for the treatment of spinal muscular atrophy (SMA), which represents the company’s primary clinical and financial focus.

The company conducts research and development activities internally while leveraging external contract research organizations for clinical trials and manufacturing partners for biologics production. Scholar Rock maintains strategic collaborations, most notably with Biogen Inc., to develop and potentially commercialize apitegromab for SMA. The company does not operate manufacturing facilities at commercial scale and has no significant revenue-generating subsidiaries as of the latest public disclosures.

Strategic Position & Investments

Scholar Rock’s strategic direction emphasizes advancing late-stage clinical assets while expanding its growth factor modulation platform into additional therapeutic areas. The company has invested heavily in its neuromuscular franchise, prioritizing the development of apitegromab following positive mid-stage clinical data, and has indicated intentions to pursue regulatory approval pathways contingent on late-stage trial outcomes.

Beyond its lead program, Scholar Rock continues to invest in earlier-stage pipeline candidates targeting cardiometabolic diseases and oncology indications linked to TGF‑β biology. The company’s collaboration with Biogen Inc. includes shared development responsibilities and milestone-based payments, representing a key external investment in its pipeline. No material acquisitions of other companies have been disclosed in recent SEC filings, and internal pipeline development remains the primary investment focus.

Geographic Footprint

Scholar Rock is headquartered in Cambridge, Massachusetts, within the United States, a major global biotechnology hub. Its executive leadership, research laboratories, and corporate functions are primarily based in this location. Clinical development activities, however, extend internationally through multi-center clinical trials conducted across North America, Europe, and other regions as required by study design.

While the company does not maintain large-scale international offices, its global footprint is established through clinical trial sites, regulatory interactions with non-U.S. authorities, and partnerships with multinational pharmaceutical companies. Its operational influence outside the United States is therefore primarily clinical and strategic rather than commercial at this stage.

Leadership & Governance

Scholar Rock was co-founded by Timothy A. Springer, whose academic work on protein biology and immunology informed the company’s scientific foundation. The company is led by executives with experience in biotechnology research, drug development, and public company governance. Management has consistently articulated a strategy centered on rigorous science, capital discipline, and focused advancement of high-impact clinical assets.

Key members of the leadership team include:

• Jay T. Backstrom – President and Chief Executive Officer
• David P. Southwell – Chief Financial Officer
• Jenna M. Glover – Chief Legal Officer and Secretary
• Mayank Mamtani – Chief Medical Officer
• Thomas J. Davis – Chief Scientific Officer

The board of directors includes individuals with backgrounds in biopharmaceutical executive leadership, clinical development, and academic science, providing governance oversight aligned with the company’s long-term research-driven strategy.